Lindus Health, the “anti-CRO” running radically faster, more reliable clinical trials for life science pioneers, has officially announced the launch of its versatile contract research organization (CRO), site, along with a technology offering tailor-made to the execution of infectious disease trials.
To understand the significance of such a development, we must acknowledge how clinical development of infectious disease treatments and diagnostics must make a consideration for complexities, such as diverse and evolving pathogens, seasonality and localization of study sites, as well as enrollment at the appropriate time during infection. Against that, Lindus leverages its industry-leading technological setup which, by the way, it has already used to facilitate the enrollment of over 5,000 patients in infectious disease studies across US and beyond.
More on the same would reveal how the company’s latest brainchild banks upon its full-spectrum CRO and site services to recruit diverse study populations at twice the speed of traditional CROs, using their expansive recruitment capabilities, including targeted digital outreach campaigns, healthcare and community organization collaborations, and electronic health record (EHR) screening from a repository of over 30 million patients.
Talk about the given solution on a slightly deeper, Lindus’ “All-in-One Infectious Disease CRO” brings to the fore full-service CRO solutions that will have the company’s clinical operations team taking care of everything from protocol writing and study startup to close-out and data delivery, overseeing all aspects concerned with infectious disease trials. These CRO solutions will also arrive on the scene with an ability to handle all project management and administrative responsibilities.
Next up, there is in play an assortment of innovative recruitment strategies. Here, the solution will effectively bank upon partnerships across primary care, urgent care, and local community groups, as well as EHR screening and direct-to-patient marketing. Furthermore, it will employ advanced methods to quickly recruit diverse patient populations in infectious disease studies.
“Infectious disease studies require swift and adaptable approaches for execution and recruitment to keep pace with evolving pathogens and public health needs,” said Meri Beckwith, co-founder of Lindus Health. “Therefore speed of execution and access to real-time data are essential, while ensuring enrollment of diverse and representative patient populations.”
Then, we have an adaptable eClinical software, where Citrusâ„¢, Lindus’ proprietary clinical research platform, custom-built for each trial, packs together essential tools, such as clinical trial management software (CTMS), electronic data capture (EDC), telehealth, and eConsent so to provide a true all-in-one solution for cohesive study management.
Hold on, we still have a couple of bits left to unpack, considering we still haven’t touched on the solution’s potential in the context of providing regulatory and industry insights. You see, at launch, Lindus would be well-equipped to offer expertise on regulatory standards and emerging developments within infectious disease research.
Another detail we haven’t yet touched upon is rooted in the offering’s comprehensive site services. Here, Lindus’ site operations team collaborates closely with principal investigators and research staff to execute women’s health trials across single-site, multi-site, hybrid, and fully virtual environments.
“The escalating prevalence and rapid evolution of infectious pathogens present significant challenges to developing interventions to treat, detect, and protect against infectious diseases,” said Dr. Robert Langer, Institute Professor at Massachusetts Institute of Technology and Scientific Advisor to Lindus Health. “With their innovative, agile approaches to trial execution, I believe Lindus Health is well-equipped to quickly adapt and overcome these challenges as they arise.”